Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression

Mauricio Tohen, Eduard Vieta, Joseph Calabrese, Terence A. Ketter, Gary Sachs, Charles Bowden, Philip B. Mitchell, Franca Centorrino, Richard Risser, Robert W. Baker, Angela R. Evans, Karin Beymer, Sanjay Dubé, Gary D. Tollefson, Alan Breier

Research output: Contribution to journalArticle

750 Citations (Scopus)

Abstract

Background: Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression. Objective: To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Design: Double-blind, 8-week, randomized controlled trial. Setting: Eighty-four sites (inpatient and outpatient) in 13 countries. Patients: A total of 833 randomized adults with bipolar I depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. Intervention: Patients were randomly assigned to receive placebo (n=377); olanzapine, 5 to 20 mg/d (n=370); or olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d (n=86). Main Outcome Measure: Changes in MADRS total scores using mixed-effects model repeated-measures analyses. Results: During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P

Original languageEnglish (US)
Pages (from-to)1079-1088
Number of pages10
JournalArchives of General Psychiatry
Volume60
Issue number11
DOIs
StatePublished - Nov 2003

Fingerprint

olanzapine
Bipolar Disorder
Depression
Placebos
Fluoxetine
Therapeutics
Antidepressive Agents
Antipsychotic Agents
Inpatients
Outpatients
Randomized Controlled Trials
Outcome Assessment (Health Care)
olanzapine-fluoxetine combination

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. / Tohen, Mauricio; Vieta, Eduard; Calabrese, Joseph; Ketter, Terence A.; Sachs, Gary; Bowden, Charles; Mitchell, Philip B.; Centorrino, Franca; Risser, Richard; Baker, Robert W.; Evans, Angela R.; Beymer, Karin; Dubé, Sanjay; Tollefson, Gary D.; Breier, Alan.

In: Archives of General Psychiatry, Vol. 60, No. 11, 11.2003, p. 1079-1088.

Research output: Contribution to journalArticle

Tohen, M, Vieta, E, Calabrese, J, Ketter, TA, Sachs, G, Bowden, C, Mitchell, PB, Centorrino, F, Risser, R, Baker, RW, Evans, AR, Beymer, K, Dubé, S, Tollefson, GD & Breier, A 2003, 'Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression', Archives of General Psychiatry, vol. 60, no. 11, pp. 1079-1088. https://doi.org/10.1001/archpsyc.60.11.1079
Tohen, Mauricio ; Vieta, Eduard ; Calabrese, Joseph ; Ketter, Terence A. ; Sachs, Gary ; Bowden, Charles ; Mitchell, Philip B. ; Centorrino, Franca ; Risser, Richard ; Baker, Robert W. ; Evans, Angela R. ; Beymer, Karin ; Dubé, Sanjay ; Tollefson, Gary D. ; Breier, Alan. / Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. In: Archives of General Psychiatry. 2003 ; Vol. 60, No. 11. pp. 1079-1088.
@article{a42bc381a44f453a991de6e5d64b7c90,
title = "Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression",
abstract = "Background: Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression. Objective: To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Design: Double-blind, 8-week, randomized controlled trial. Setting: Eighty-four sites (inpatient and outpatient) in 13 countries. Patients: A total of 833 randomized adults with bipolar I depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. Intervention: Patients were randomly assigned to receive placebo (n=377); olanzapine, 5 to 20 mg/d (n=370); or olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d (n=86). Main Outcome Measure: Changes in MADRS total scores using mixed-effects model repeated-measures analyses. Results: During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P",
author = "Mauricio Tohen and Eduard Vieta and Joseph Calabrese and Ketter, {Terence A.} and Gary Sachs and Charles Bowden and Mitchell, {Philip B.} and Franca Centorrino and Richard Risser and Baker, {Robert W.} and Evans, {Angela R.} and Karin Beymer and Sanjay Dub{\'e} and Tollefson, {Gary D.} and Alan Breier",
year = "2003",
month = "11",
doi = "10.1001/archpsyc.60.11.1079",
language = "English (US)",
volume = "60",
pages = "1079--1088",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression

AU - Tohen, Mauricio

AU - Vieta, Eduard

AU - Calabrese, Joseph

AU - Ketter, Terence A.

AU - Sachs, Gary

AU - Bowden, Charles

AU - Mitchell, Philip B.

AU - Centorrino, Franca

AU - Risser, Richard

AU - Baker, Robert W.

AU - Evans, Angela R.

AU - Beymer, Karin

AU - Dubé, Sanjay

AU - Tollefson, Gary D.

AU - Breier, Alan

PY - 2003/11

Y1 - 2003/11

N2 - Background: Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression. Objective: To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Design: Double-blind, 8-week, randomized controlled trial. Setting: Eighty-four sites (inpatient and outpatient) in 13 countries. Patients: A total of 833 randomized adults with bipolar I depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. Intervention: Patients were randomly assigned to receive placebo (n=377); olanzapine, 5 to 20 mg/d (n=370); or olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d (n=86). Main Outcome Measure: Changes in MADRS total scores using mixed-effects model repeated-measures analyses. Results: During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P

AB - Background: Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression. Objective: To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Design: Double-blind, 8-week, randomized controlled trial. Setting: Eighty-four sites (inpatient and outpatient) in 13 countries. Patients: A total of 833 randomized adults with bipolar I depression with a Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 20. Intervention: Patients were randomly assigned to receive placebo (n=377); olanzapine, 5 to 20 mg/d (n=370); or olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d (n=86). Main Outcome Measure: Changes in MADRS total scores using mixed-effects model repeated-measures analyses. Results: During all 8 study weeks, the olanzapine and olanzapine-fluoxetine groups showed statistically significant improvement in depressive symptoms vs the placebo group (P

UR - http://www.scopus.com/inward/record.url?scp=10744220918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220918&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.60.11.1079

DO - 10.1001/archpsyc.60.11.1079

M3 - Article

C2 - 14609883

AN - SCOPUS:10744220918

VL - 60

SP - 1079

EP - 1088

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 11

ER -